Advanced searches left 3/3

Cardiac Autonomic Neuropathy - Europe PMC

Summarized by Plex Scholar
Last Updated: 09 August 2022

* If you want to update the article please login/register

SGLT2-inhibitors reduce the cardiac autonomic neuropathy dysfunction and vaso-vagal syncope recurrence in patients with type 2 diabetes mellitus: the SCAN study.

Patients with VVS could be able to modulate/reduce autonomic dysfunction in T2DM patients. Methods The study was conducted in a prospective multicenter study, after propensity score matching, and a population of 324 T2DM patients with VVS was divided into 161 SGLT2-I-I users vs. 163 Non-SGLT2-I users. At 12 months of follow-up, we investigated the HRV and 123I-MIBG variations and VVS recurrence in these patients as SGLT2-I-users vs. Non-SGLT2-I-users. SGLT2-I-I-Probes showed the best glucose homeostasis and lower blood pressures, as well as resting heart rate at the end of the review The SGLT2-I-I-i users vs. Non-SGLT2-I-I users had the highest glucose homeostasis and lower values of inflammatory markers at the end of the study, as well as resting heart rate. Finally, when comparing SGLT2-I-users vs. Non-SGLT2-I-users, we discovered a higher incidence of VVS recurrence events, particularly in the vasodepressor VVS recurrence at a 1-year follow-up. The VVS recurrence was predicted by the indexes of cardiac denervation, while the SGLT2-I reduced the possibility of VVS recurrence.

Source link: https://europepmc.org/article/MED/35732222


Association between plasma apolipoprotein M and cardiac autonomic neuropathy in type 1 diabetes.

The present study was designed to see if plasma apoM was related to an elevated risk of CAN. Methods The study includes 278 people with Type 1 Diabetes who were recruited from the Steno Diabetes Center in Copenhagen from 2010 to 2012. When adjusted for age and gender, as well as lipids, beta-blockers, blood pressure, and alcohol, as well as diabetes and Hbga1c, were all positively correlated with CAN. In all adjusted models, Plasma apoM was also associated with a significantly reduced SDNN as well as high frequency power.

Source link: https://europepmc.org/article/MED/35690270


Metformin-induced vitamin B12 deficiency can cause or worsen distal symmetrical, autonomic and cardiac neuropathy in the patient with diabetes.

Vitamin B12 depletion in all patients who use metformin, especially if metformin has been used for more than five years, so regular testing of vitamin B12 is encouraged in all patients who use metformin, particularly in the case of metformin, is likely to be depleted. Vitamin B12 deficiency can be detected early in childhood if serum vitamin B12 levels are borderline; measurement of methylmalonic acid and homocysteine levels can reveal vitamin B12 deficiency at the earliest stage. If metformin is used, therapies include prophylactic calcium and vitamin B12 supplements, metformin withdrawal, supplementing vitamin B12 stores with intramuscular or oral vitamin B12 therapy, and regular monitoring of vitamin B12 levels and vitamin B12 supplements. Objective measures of neuropathy stability remain stable but don't change with adequate vitamin B12 replacement, although signs of neuropathy may or may not improve, but do not improve.

Source link: https://europepmc.org/article/MED/35491956

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions